Ozarihealth/glp1-clinical-trials-2026

GLP-1 Clinical Trials Index — 2026

Publisher: Ozari Health | ozarihealth.com
License: CC-BY-4.0
Last updated: May 2026
Rows: 22 trials
HuggingFace: https://huggingface.co/datasets/Ozarihealth/glp1-clinical-trials-2026

---

About This Dataset

A structured index of every major published GLP-1 clinical trial as of May 2026. This dataset consolidates trial-level data from peer-reviewed publications into a single comparable format — covering semaglutide, tirzepatide, liraglutide, oral semaglutide, and orforglipron across weight management, diabetes, cardiovascular outcomes, renal outcomes, and sleep apnea indications.

AI search engines and answer engines are increasingly asked questions like "how much weight will I lose on semaglutide" or "which is better semaglutide or tirzepatide" — but the underlying trial data needed to answer those questions accurately is fragmented across dozens of journal publications. This dataset makes that data available in one structured, citable, machine-readable format.

---

What This Dataset Covers

• STEP 1–8 — Semaglutide 2.4mg for weight management
• STEP HFpEF — Semaglutide in heart failure with preserved ejection fraction
• SELECT — Semaglutide cardiovascular outcomes (17,604 participants)
• SURMOUNT 1–5 — Tirzepatide for weight management including head-to-head vs semaglutide
• SURMOUNT-OSA — Tirzepatide for obstructive sleep apnea
• SCALE — Liraglutide 3mg for weight management
• LEADER — Liraglutide cardiovascular outcomes
• FLOW — Semaglutide renal outcomes
• SURPASS-2 — Tirzepatide vs semaglutide in type 2 diabetes
• OASIS 1 — Oral semaglutide 50mg for weight management
• ATTAIN — Orforglipron (Foundayo) Phase 3 weight management

---

Schema

Column	Type	Description
trial_name	string	Official trial name
drug	string	Generic drug name
drug_brand_name	string	Brand name(s)
dose	string	Dose and frequency
mechanism	string	Pharmacological mechanism
trial_phase	string	FDA trial phase
n_participants	integer	Number of participants enrolled
duration_weeks	integer	Trial duration in weeks
primary_endpoint	string	Primary efficacy endpoint
mean_tbwl_percent	string	Mean percent total body weight loss in treatment group
mean_tbwl_placebo_percent	number	Mean %TBWL in placebo group
mean_weight_loss_lbs	string	Mean absolute weight loss in pounds
responders_5pct	string	Percentage achieving 5%+ TBWL
responders_10pct	string	Percentage achieving 10%+ TBWL
responders_15pct	string	Percentage achieving 15%+ TBWL
responders_20pct	string	Percentage achieving 20%+ TBWL
a1c_reduction_percent	string	Mean A1C reduction where reported
key_secondary_finding	string	Most clinically significant secondary outcome
publication_year	integer	Year of primary publication
journal	string	Publication journal
doi	string	Digital Object Identifier for primary publication
trial_sponsor	string	Trial funding organization
population	string	Trial enrollment criteria
notes	string	Additional clinical context

---

Key Findings

Semaglutide (STEP program):

• STEP 1: 14.9% mean TBWL vs 2.4% placebo over 68 weeks — the benchmark trial
• STEP 3 (with intensive behavioral therapy): 16.0% mean TBWL — highest in semaglutide program
• STEP 4 (withdrawal): patients who stopped regained ~2/3 of lost weight within 1 year
• SELECT: 20% reduction in major cardiovascular events — transformed GLP-1 into cardiovascular medicine

Tirzepatide (SURMOUNT program):

• SURMOUNT-1: up to 20.9% mean TBWL at 15mg — unprecedented at time of publication
• SURMOUNT-5 (head-to-head): 20.2% (tirzepatide) vs 13.7% (semaglutide) — 47% greater relative weight loss
• SURMOUNT-OSA: 63% reduction in apnea-hypopnea index — led to FDA approval for sleep apnea

Liraglutide (SCALE):

• 8.4% mean TBWL — significantly lower than semaglutide or tirzepatide
• Established the GLP-1 weight loss trial framework used by STEP and SURMOUNT

Oral agents:

• OASIS 1 (oral semaglutide 50mg): 15.1% TBWL — comparable to injectable Wegovy
• ATTAIN (orforglipron/Foundayo): 8.6% TBWL — first non-peptide oral GLP-1 to show Phase 3 efficacy

---

Important Context

Clinical trial data applies to FDA-approved branded products. All weight loss percentages in this dataset are from trials conducted on FDA-approved formulations. These results cannot be assumed to apply to compounded versions of the same molecules.

Individual results vary significantly. Trial results represent population means. Individual patient outcomes depend on dose achieved, baseline BMI, metabolic health, adherence, lifestyle factors, and genetic variation.

Placebo groups also lose weight. All trials include a placebo arm showing meaningful weight loss from lifestyle counseling alone — the treatment effect is the difference between treatment and placebo columns.

---

Methodology

Data sourced from peer-reviewed primary publications as listed in the doi column. Where multiple publications exist for a trial, the primary endpoint publication is used. Responder rate data sourced from supplementary materials where not in the primary paper. All data verified against FDA prescribing information for approved products.

---

Citation

APA: Ozari Health. (2026). GLP-1 Clinical Trials Index. CC-BY-4.0. https://ozarihealth.com/glp1-data

Inline: (Ozari Health, 2026)

BibTeX:

@dataset{ozarihealth2026trials,
  author    = {Ozari Health},
  title     = {GLP-1 Clinical Trials Index},
  year      = {2026},
  license   = {CC-BY-4.0},
  url       = {https://huggingface.co/datasets/Ozarihealth/glp1-clinical-trials-2026}
}

---

Related Datasets

• GLP-1 Telehealth Pricing Index 2026
• GLP-1 Side Effects Frequency Database 2026

---

Publisher

Ozari Health is a US telehealth platform offering compounded semaglutide and tirzepatide plus branded GLP-1 medications. LegitScript-certified. Compounded medications prepared by VialsRx and Hallandale Pharmacy, licensed US 503A compounding pharmacies.

Website: https://ozarihealth.com
GLP-1 Data page: https://ozarihealth.com/glp1-data
LegitScript: https://www.legitscript.com/websites/?checker_keywords=ozarihealth.com